Tricol Biomedical, Inc.
Tricol Biomedical is dedicated to saving lives through innovative hemostatic and wound care solutions. With a focus on quality and innovation, the company develops, manufactures, and markets proprietary products like Chito+™, HemCon®, and OneStop™ to control bleeding and manage wounds in various medical settings. Born on the battlefield, Tricol's products are used globally to address trauma, procedural, and consumer self-care needs, with a mission to achieve zero preventable deaths due to blood loss.
Industries
Nr. of Employees
small (1-50)
Tricol Biomedical, Inc.
720 SW Washington Street, Suite 200, Portland, Oregon 97205-3504 USA
Patents
Bioadhesive chitosan gel for controlling bleeding and for promoting healing with scar reduction without obscuring or interfering with access to a surgical field
US-11160901-B2
View Details
Bioadhesive chitosan gel for controlling bleeding and for promoting healing with scar reduction without obscuring or interfering with access to a surgical field
US-11160901-B2
View DetailsProducts
Chitosan-based hemostatic dressings
Topical hemostatic dressings composed of mucoadhesive chitosan for rapid adhesion to injured tissue, wound sealing, and bacterial barrier properties; available in gauze, bandage, dot patch, and vascular patch formats for trauma, procedural, and consumer use.
Oxidized-cellulose hemostatic dressings
Micro-dispersed oxidized cellulose products that activate intrinsic coagulation enzymes and form a gel-like matrix to retain clot material and support hemostasis in surgical and procedural contexts.
Vascular closure patches and compression-device integrated solutions
Hemostatic patches designed for vascular access sites and for use with external compression devices to support closure workflows after percutaneous procedures.
Investigational absorbable implantable chitosan dressing
An investigational absorbable chitosan dressing designed for internal bleeding control with demonstrated staged bioabsorption and biocompatibility in preclinical models; not cleared for internal use in clinical practice.
Chitosan-based hemostatic dressings
Topical hemostatic dressings composed of mucoadhesive chitosan for rapid adhesion to injured tissue, wound sealing, and bacterial barrier properties; available in gauze, bandage, dot patch, and vascular patch formats for trauma, procedural, and consumer use.
Oxidized-cellulose hemostatic dressings
Micro-dispersed oxidized cellulose products that activate intrinsic coagulation enzymes and form a gel-like matrix to retain clot material and support hemostasis in surgical and procedural contexts.
Vascular closure patches and compression-device integrated solutions
Hemostatic patches designed for vascular access sites and for use with external compression devices to support closure workflows after percutaneous procedures.
Investigational absorbable implantable chitosan dressing
An investigational absorbable chitosan dressing designed for internal bleeding control with demonstrated staged bioabsorption and biocompatibility in preclinical models; not cleared for internal use in clinical practice.
Services
Collaborative product development, private-label/co-branding, and contract manufacturing support for partner medical device companies and distributors, including supplier and regulatory coordination.
Provision of product samples via a request form that collects evaluator and facility information, with options to ship to the evaluating facility or a representative; includes a standardized feedback form to document clinical evaluation outcomes.
Management of international distributor relationships and group purchasing organization agreements to enable hospital and clinical access.
Licensing of patented biomaterial compositions and delivery technologies under exclusive or non-exclusive agreements.
Collaborative product development, private-label/co-branding, and contract manufacturing support for partner medical device companies and distributors, including supplier and regulatory coordination.
Provision of product samples via a request form that collects evaluator and facility information, with options to ship to the evaluating facility or a representative; includes a standardized feedback form to document clinical evaluation outcomes.
Management of international distributor relationships and group purchasing organization agreements to enable hospital and clinical access.
Licensing of patented biomaterial compositions and delivery technologies under exclusive or non-exclusive agreements.
Expertise Areas
- Hemostasis device development
- Biomaterials (chitosan and oxidized cellulose)
- Preclinical testing and biocompatibility
- Medical device manufacturing and scale-up
Key Technologies
- Chitosan-based mucoadhesive hemostats
- Bioabsorbable chitosan implantable dressings
- Oxidized cellulose hemostatic materials
- Endoluminal / through-the-scope delivery concepts
News & Updates
The US Patent and Trademark Office granted Tricol Biomedical a new patent for a modified chitosan dressing for gastrointestinal bleeding, providing easy delivery and prolonged use.
Tricol expanded its GPO agreements to include the OneStop™ Vascular line and developed an exclusive U.S. distribution agreement with Salvin Dental Specialties for HemCon® Dental Dressing PRO.
MedTech Outlook recognized Tricol as a top wound care solutions provider, highlighting its innovative technologies like Chito+™ for bleeding control in and out of the hospital.
An article discussing Tricol's proprietary chitosan technology and its applications in trauma and medical procedures.
A study demonstrating the bioabsorption and biocompatibility of ABC dressing in animal models, indicating its potential for internal bleeding management.
Tricol received an $853,585 grant from NIH to develop a hemostatic device for prostate bleeding, addressing a significant unmet medical need.
The US Patent and Trademark Office granted Tricol Biomedical a new patent for a modified chitosan dressing for gastrointestinal bleeding, providing easy delivery and prolonged use.
Tricol expanded its GPO agreements to include the OneStop™ Vascular line and developed an exclusive U.S. distribution agreement with Salvin Dental Specialties for HemCon® Dental Dressing PRO.
MedTech Outlook recognized Tricol as a top wound care solutions provider, highlighting its innovative technologies like Chito+™ for bleeding control in and out of the hospital.
An article discussing Tricol's proprietary chitosan technology and its applications in trauma and medical procedures.
A study demonstrating the bioabsorption and biocompatibility of ABC dressing in animal models, indicating its potential for internal bleeding management.
Tricol received an $853,585 grant from NIH to develop a hemostatic device for prostate bleeding, addressing a significant unmet medical need.